GT Biopharma Inc. (GTBP) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
315 MONTGOMERY STREET SAN FRANCISCO, CA 94104 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments, including: | 14,000 | 16,508 | 32,000 | 5,297 | 28 | 60 | |||
| Cash and cash equivalents | 1,079 | 5,672 | 9,218 | 5,297 | 28 | 60 | |||
| Short-term investments | 12,893 | 10,836 | 23,011 | ||||||
| Other undisclosed cash, cash equivalents, and short-term investments | 28 | (229) | |||||||
| Restricted cash and investments | |||||||||
| Prepaid expense | 190 | 364 | 246 | 30 | |||||
| Other undisclosed current assets | 56 | 54 | (21) | ||||||
| Total current assets: | 14,056 | 16,562 | 32,169 | 5,661 | 274 | 90 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 53 | 165 | ✕ | ||||||
| Property, plant and equipment | 35 | ||||||||
| Intangible assets, net (including goodwill), including: | 25,262 | ||||||||
| Other undisclosed intangible assets, net (including goodwill) | 25,262 | ||||||||
| Deposits noncurrent assets | 9 | 12 | 12 | ||||||
| Other undisclosed noncurrent assets | 110 | ||||||||
| Total noncurrent assets: | 53 | 174 | 122 | 25,309 | |||||
| TOTAL ASSETS: | 14,109 | 16,736 | 32,169 | 5,661 | 396 | 25,399 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 5,523 | 4,809 | 10,090 | 8,377 | 6,348 | 3,217 | |||
| Interest and dividends payable | ✕ | ✕ | ✕ | 4,838 | 2,029 | ||||
| Accounts payable | 4,328 | 3,140 | 8,189 | 2,243 | 1,940 | 1,762 | |||
| Accrued liabilities | 1,195 | 1,669 | 1,901 | 1,296 | 2,379 | 1,455 | |||
| Debt | 31 | 26,303 | 13,207 | 10,673 | |||||
| Deferred rent credit | 8 | ||||||||
| Derivative instruments and hedges, liabilities | 19 | 138 | 383 | ||||||
| Due to related parties | ✕ | ✕ | 100 | ||||||
| Other undisclosed current liabilities | 1,110 | 110 | 31 | 151 | 31 | ||||
| Total current liabilities: | 6,633 | 4,938 | 10,259 | 35,094 | 19,706 | 14,029 | |||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt | 64 | ||||||||
| Operating lease, liability | 64 | ✕ | |||||||
| Total noncurrent liabilities: | 64 | ||||||||
| Total liabilities: | 6,633 | 5,002 | 10,259 | 35,094 | 19,706 | 14,029 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | 7,476 | 11,734 | 21,910 | (29,433) | (19,310) | 11,370 | |||
| Preferred stock | 1 | 1 | 3 | ||||||
| Common stock | 1 | 33 | 32 | 52 | 70 | 51 | |||
| Additional paid in capital | 689,539 | 686,168 | 674,348 | 566,309 | 548,118 | 540,171 | |||
| Accumulated deficit | (682,065) | (674,468) | (653,584) | (595,628) | (567,332) | (528,685) | |||
| Other undisclosed equity, attributable to parent | 1,114 | (169) | (166) | (167) | |||||
| Total equity: | 7,476 | 11,734 | 21,910 | (29,433) | (19,310) | 11,370 | |||
| TOTAL LIABILITIES AND EQUITY: | 14,109 | 16,736 | 32,169 | 5,661 | 396 | 25,399 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues (gain on Disposition of Assets for Financial Service Operations) | 31,979 | |||||||
| Gross profit: | 31,979 | |||||||
| Operating expenses | (13,576) | (21,257) | (57,515) | (6,764) | (16,056) | (250,069) | ||
| Other undisclosed operating income (loss) | (31,979) | 13,528 | ||||||
| Operating income (loss): | (13,576) | (21,257) | (57,515) | 6,764 | (16,056) | (250,069) | ||
| Nonoperating income (expense) | 5,979 | 373 | (498) | 21,532 | (22,591) | (9,117) | ||
| Investment income, nonoperating | 12,598 | (4,599) | (228,515) | |||||
| Other nonoperating income (expense) | 20 | 38 | ||||||
| Interest and debt expense | (213) | 31 | 3,003 | (2,128) | (9,117) | |||
| Income (loss) from continuing operations before equity method investments, income taxes: | (7,810) | (20,853) | (58,013) | 31,299 | (40,775) | (268,303) | ||
| Other undisclosed income from continuing operations before income taxes | 2,128 | 9,117 | ||||||
| Income (loss) from continuing operations: | (7,810) | (20,853) | (58,013) | 31,299 | (38,647) | (259,186) | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (58,013) | 31,299 | (38,647) | (259,186) | |
| Net income (loss): | (7,810) | (20,853) | (58,013) | 31,299 | (38,647) | (259,186) | ||
| Other undisclosed net income (loss) attributable to parent | 213 | (31) | (59,595) | |||||
| Net loss available to common stockholders, diluted: | (7,597) | (20,884) | (58,013) | (28,296) | (38,647) | (259,186) | ||
Comprehensive Income ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (7,810) | (20,853) | (58,013) | 31,299 | (38,647) | (259,186) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (7,810) | (20,853) | (58,013) | 31,299 | (38,647) | (259,186) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.